rs121913496
Variant summary
Our verdict is Likely pathogenic. Variant got 6 ACMG points: 6P and 0B. PM2PP3_ModeratePP5_Moderate
The NM_001318054.2(HRAS):c.-137G>T variant causes a 5 prime UTR premature start codon gain change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★).
Frequency
Consequence
NM_001318054.2 5_prime_UTR_premature_start_codon_gain
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 6 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
HRAS | ENST00000311189.8 | c.183G>T | p.Gln61His | missense_variant | Exon 3 of 6 | 1 | NM_005343.4 | ENSP00000309845.7 | ||
HRAS | ENST00000417302.7 | c.183G>T | p.Gln61His | missense_variant | Exon 3 of 6 | 5 | NM_176795.5 | ENSP00000388246.1 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 34
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Noonan syndrome 3 Pathogenic:1
Variant summary: The HRAS c.183G>T (p.Gln61His) variant causes a missense change involving the alteration of a non-conserved nucleotide. 2/4 in silico tools predict a benign outcome for this variant (SNPsandGO not captured due to low reliability index). The variant alters a GEF interaction site of conserved H_Ras_like domain and was shown to have a reduced hydrolyzed GTPase activity resulting in a constitutively active protein (Bollag, 1991; Der 1986). The variant of interest is absent from broad control datasets of ExAC or gnomAD (~100996 and 276982 chrs tested, respectively). The variant has not, to our knowledge, been reported as germline mutation in individuals diagnosed with Costello (CS) or Noonan Spectrum Related Disorders (NSRD) via publications and/or reputable databases/clinical diagnostic laboratories. Oncogenic Ras codons 12, 13 and 61 are well known as the primary sites where activating somatic mutations result in a constitutively active protein characterized by a reduced GAP action and/or intrinsic GTPase activity. The p.Gln61His is vastly reported in the literature as a somatic variant, identified in melanoma, metaplastic breast carcinoma, lung cancer, head and neck cancer, and other types of tumors. The c.183G>T was identified in a prenatal sample with negative MCC referred for genetic testing due to abnormal ultrasound finding (cystic hygroma, fetal edema and cardiac defect). Considering all evidence and ACMG guidelines, the variant of interest is classified as Likely Pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at